Abstract
PURPOSE: The purpose of this study was to evaluate patient, prescriber, and dose characteristics and evaluate changes in glycated hemoglobin (HbA(1c)) for patients prescribed once weekly semaglutide for diabetes (OW sema T2D). METHODS: This study was a retrospective claims-based study using the Optum Research Database. The sample included adult patients who had at least one claim for OW sema T2D between Jan 1, 2018, and Dec 31, 2019, were continuously enrolled in the health plan and had a diagnosis of type 2 diabetes (T2DM) during the pre-index or post-index periods. Demographic and clinical characteristics of patients using OW sema T2D were collected, as were the dose and prescriber specialty and the change between pre-index and post-index HbA(1c) measures was calculated. Results were stratified by the latest pre-index HbA(1c) measurement (HbA(1c) greater than or equal to 9.0%, uncontrolled vs. HbA(1c) less than 9%, controlled). Statistical comparisons between HbA(1c) groups were conducted. RESULTS: Most patients, 76.3%, were prescribed a 0.25/0.50 mg dose of OW sema T2D. Patients had an overall decrease in HbA(1c) of 0.8% and patients with uncontrolled diabetes had a greater reduction in mean HbA(1c) compared to those with controlled diabetes (-2.1% vs. -0.3%, p < 0.001). Most patients had their index dose of OW sema T2D prescribed by endocrinologists (27.6%) primary care providers (24.6%) and internal medicine providers (21.6%). CONCLUSIONS: OW sema T2D is an effective real-world T2DM treatment. Future research should further investigate real-world use patterns of this medication.